* **Short Interest Surge:** Elevai Labs experienced a substantial increase in short interest during August, raising concerns among investors. * **Stock Price Decline:** The company’s stock price has been declining, contributing to the rise in short interest.

Get Elevai Labs alerts: Elevai Labs (NASDAQ:ELAB – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter. Elevai Labs had a negative return on equity of 216.19% and a negative net margin of 191.96%. The company had revenue of $0.61 million during the quarter. Institutional Investors Weigh In On Elevai Labs Elevai Labs Company Profile A hedge fund recently bought a new stake in Elevai Labs stock. Diversify Advisory Services LLC acquired a new position in Elevai Labs, Inc. ( NASDAQ:ELAB Free Report ) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 52,500 shares of the company’s stock, valued at approximately $36,000. Diversify Advisory Services LLC owned approximately 0.30% of Elevai Labs as of its most recent filing with the Securities and Exchange Commission. 22.22% of the stock is currently owned by institutional investors and hedge funds.

(Get Free Report) Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021. Further Reading Receive News & Ratings for Elevai Labs Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elevai Labs and related companies with MarketBeat.com’s FREE daily email newsletter.